These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
485 related articles for article (PubMed ID: 20537753)
61. TIPS for management of refractory ascites: response and survival are both unpredictable. Thuluvath PJ; Bal JS; Mitchell S; Lund G; Venbrux A Dig Dis Sci; 2003 Mar; 48(3):542-50. PubMed ID: 12757168 [TBL] [Abstract][Full Text] [Related]
62. Two-stage transjugular intrahepatic porta-systemic shunt for patients with cirrhosis and a high risk of portal-systemic encephalopathy patients as a bridge to orthotopic liver transplantation: a preliminary report. Wróblewski T; Rowiński O; Ziarkiewicz-Wróblewska B; Górnicka B; Albrecht J; Jones EA; Krawczyk M Transplant Proc; 2006; 38(1):204-8. PubMed ID: 16504703 [TBL] [Abstract][Full Text] [Related]
63. [Transjugular intrahepatic portosystemic shunt in the treatment of refractory ascites in 21 patients]. Vandistel G; Nevens F; Stockx L; Raat H; Wilms G; Fevery J Ned Tijdschr Geneeskd; 1996 Dec; 140(49):2455-8. PubMed ID: 8999346 [TBL] [Abstract][Full Text] [Related]
65. Uncovering the truth about covered stents: is there a difference between covered versus uncovered stents with transjugular intrahepatic portosystemic shunts? Clark W; Golkar F; Luberice K; Toomey P; Paul H; Marcadis A; Okpaleke C; Vice M; Hernandez J; Alsina A; Rosemurgy AS Am J Surg; 2011 Nov; 202(5):561-4. PubMed ID: 21944293 [TBL] [Abstract][Full Text] [Related]
66. Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review. Qi XS; Bai M; Yang ZP; Fan DM World J Gastroenterol; 2014 Jun; 20(21):6470-80. PubMed ID: 24914368 [TBL] [Abstract][Full Text] [Related]
67. Transjugular intrahepatic portosystemic shunt--role in treating intractable variceal bleeding, ascites, and hepatic hydrothorax. LaBerge JM Clin Liver Dis; 2006 Aug; 10(3):583-98, ix. PubMed ID: 17162229 [TBL] [Abstract][Full Text] [Related]
68. TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts. Bercu ZL; Fischman AM; Kim E; Nowakowski FS; Patel RS; Schiano TD; Chang CY; Lookstein RA AJR Am J Roentgenol; 2015 Mar; 204(3):654-61. PubMed ID: 25714299 [TBL] [Abstract][Full Text] [Related]
69. [Transjugular placement of an intrahepatic portosystemic shunt as current treatment for complications of portal hypertension]. Buiskool RA; Pieterman H; van Buuren HR; Laméris JS Ned Tijdschr Geneeskd; 1996 Mar; 140(12):659-64. PubMed ID: 8668239 [TBL] [Abstract][Full Text] [Related]
70. Cirrhotic patients with a transjugular intrahepatic portosystemic shunt undergoing major extrahepatic surgery. Kim JJ; Dasika NL; Yu E; Fontana RJ J Clin Gastroenterol; 2009 Jul; 43(6):574-9. PubMed ID: 19169145 [TBL] [Abstract][Full Text] [Related]
71. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Riggio O; Angeloni S; Salvatori FM; De Santis A; Cerini F; Farcomeni A; Attili AF; Merli M Am J Gastroenterol; 2008 Nov; 103(11):2738-46. PubMed ID: 18775022 [TBL] [Abstract][Full Text] [Related]
72. [Transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of complications of portal hypertension in patients with liver cirrhosis]. Grønbaek H; Astrup LB; Nielsen DT; Vilstrup H Ugeskr Laeger; 2003 Jan; 165(5):439-42. PubMed ID: 12599838 [TBL] [Abstract][Full Text] [Related]
73. Smaller-Diameter Covered Transjugular Intrahepatic Portosystemic Shunt Stents Are Associated With Increased Survival. Trebicka J; Bastgen D; Byrtus J; Praktiknjo M; Terstiegen S; Meyer C; Thomas D; Fimmers R; Treitl M; Euringer W; Sauerbruch T; Rössle M Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2793-2799.e1. PubMed ID: 30940552 [TBL] [Abstract][Full Text] [Related]
74. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests. Baron A; Gulberg V; Sauter G; Waggershauser T; Reiser M; Gerbes AL Hepatogastroenterology; 1998; 45(24):2315-21. PubMed ID: 9951915 [TBL] [Abstract][Full Text] [Related]
75. [Effects of percutaneous intrahepatic portosystemic shunt on splanchnic and systemic hemodynamics in patients with portal hypertension]. François E; García-Pagán JC; Bru C; Feu F; Gilabert R; Escorsell A; Bosch J; Rodés J Gastroenterol Hepatol; 1997 Jan; 20(1):1-4. PubMed ID: 9072189 [TBL] [Abstract][Full Text] [Related]
76. A case-controlled study of the safety and efficacy of transjugular intrahepatic portosystemic shunts after liver transplantation. King A; Masterton G; Gunson B; Olliff S; Redhead D; Mangat K; Oniscu G; Hayes P; Tripathi D Liver Transpl; 2011 Jul; 17(7):771-8. PubMed ID: 21714062 [TBL] [Abstract][Full Text] [Related]
77. Transjugular intrahepatic portosystemic shunt does not alter cerebral blood flow. Iversen P; Keiding S; Mouridsen K; Ott P; Vilstrup H Clin Gastroenterol Hepatol; 2011 Nov; 9(11):1001-3. PubMed ID: 21806953 [TBL] [Abstract][Full Text] [Related]
78. Transjugular intrahepatic portosystemic shunts in hemodialysis-dependent patients and patients with advanced renal insufficiency: safety, caution, and encephalopathy. Haskal ZJ; Radhakrishnan J J Vasc Interv Radiol; 2008 Apr; 19(4):516-20. PubMed ID: 18375295 [TBL] [Abstract][Full Text] [Related]
79. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis. Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458 [TBL] [Abstract][Full Text] [Related]